Corvus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Corvus Pharmaceuticals
CRVS Stock  USD 5.01  0.28  5.92%   
Corvus Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Corvus Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Corvus Pharmaceuticals financial statements helps investors assess Corvus Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Corvus Pharmaceuticals' valuation are summarized below:
Market Capitalization
321.9 M
Earnings Share
(1.05)
There are over one hundred nineteen available fundamental signals for Corvus Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should validate Corvus Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 140.7 M in 2025, whereas Enterprise Value is likely to drop slightly above 80.6 M in 2025.
Check Corvus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corvus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 129.1 K, Interest Expense of 1.9 M or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.06. Corvus financial statements analysis is a perfect complement when working with Corvus Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Corvus Pharmaceuticals Correlation against competitors.
For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.

Corvus Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets68.5 M41 M63.5 M
Slightly volatile
Short and Long Term Debt Total2.1 M1.2 M2.6 M
Slightly volatile
Other Current Liabilities6.1 M4.6 M4.8 M
Slightly volatile
Total Current Liabilities9.7 M7.9 M7.3 M
Slightly volatile
Other Liabilities870.8 K999.4 K636.6 K
Slightly volatile
Accounts Payable2.2 M1.8 M1.5 M
Slightly volatile
Cash10.8 M11.4 M33.7 M
Very volatile
Other Assets0.860.9549.3 K
Slightly volatile
Cash And Short Term Investments23.2 M24.4 M50.3 M
Pretty Stable
Common Stock Shares Outstanding30.7 M55.2 M22.9 M
Slightly volatile
Short Term Investments12.4 M13.1 M60.5 M
Slightly volatile
Liabilities And Stockholders Equity68.5 M41 M63.5 M
Slightly volatile
Other Current Assets687.3 K855.6 K489.9 K
Slightly volatile
Total Liabilities5.9 M6.2 M18 M
Pretty Stable
Total Current Assets23.9 M25.2 M50.6 M
Pretty Stable
Common Stock3.5 K5.8 K3.1 K
Slightly volatile
Property Plant Equipment3 M4.2 M2.7 M
Slightly volatile
Property Plant And Equipment Net1.8 M1.2 M2.1 M
Very volatile
Non Current Assets Total18 M20.2 M12.4 M
Slightly volatile
Non Currrent Assets Other76.1 K80.1 K1.3 M
Very volatile
Net Receivables68.8 K72.5 K294.2 K
Slightly volatile
Capital Surpluse233.5 M339.6 M170.9 M
Slightly volatile
Property Plant And Equipment Gross7.3 M7 M3.2 M
Slightly volatile
Common Stock Total Equity2.9 K3.5 K2.5 K
Slightly volatile
Non Current Liabilities Other18.4 K9.9 K21.9 K
Slightly volatile
Net Invested Capital60.6 M34.8 M76.2 M
Slightly volatile
Net Working Capital18 M19 M63.9 M
Slightly volatile
Capital Stock4.4 K5.8 K3.6 K
Slightly volatile
Capital Lease Obligations2.1 M1.2 M2.8 M
Slightly volatile
Long Term Investments21.9 M14.5 M32.4 M
Slightly volatile

Corvus Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization129.1 K135.9 K370.4 K
Pretty Stable
Selling General Administrative8.6 M7.9 M6 M
Slightly volatile
Other Operating Expenses37.8 M26.9 M25.6 M
Slightly volatile
Research Development29.2 M19 M19.6 M
Slightly volatile
Total Operating Expenses37.8 M26.7 M25.6 M
Slightly volatile
Interest Income5.1 K5.4 K7 M
Slightly volatile
Non Operating Income Net Other45.9 M43.7 M15.7 M
Slightly volatile
Reconciled Depreciation185.5 K195.3 K648.9 K
Slightly volatile

Corvus Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.1 M1.2 M15.1 M
Pretty Stable
Depreciation165 K173.7 K366.4 K
Pretty Stable
Capital Expenditures29.1 K30.6 K860.7 K
Slightly volatile
Total Cash From Financing Activities6.7 M7.1 M24.2 M
Pretty Stable
End Period Cash Flow24 M14.5 M19.4 M
Pretty Stable
Stock Based Compensation3.5 M1.9 M3 M
Slightly volatile
Begin Period Cash Flow25 M15.1 M19.2 M
Slightly volatile
Issuance Of Capital Stock6.7 M7.1 M42.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.250.264.8059
Slightly volatile
Payables Turnover0.110.0990.1768
Pretty Stable
Cash Per Share0.620.6525.7498
Slightly volatile
Days Payables Outstanding3.5 K3.3 K2.7 K
Slightly volatile
Income Quality0.990.81.037
Pretty Stable
Current Ratio4.454.688.024
Pretty Stable
Graham Number3.493.677.1837
Pretty Stable
Capex Per Share8.0E-48.0E-40.0434
Slightly volatile
Interest Debt Per Share0.06730.07084.8345
Slightly volatile
Debt To Assets0.06860.03470.0913
Slightly volatile
Days Of Payables Outstanding3.5 K3.3 K2.7 K
Slightly volatile
Ebt Per Ebit1.21.331.4838
Slightly volatile
Long Term Debt To Capitalization0.02710.02750.0287
Slightly volatile
Total Debt To Capitalization0.03750.03940.3602
Slightly volatile
Quick Ratio4.454.688.0426
Pretty Stable
Net Income Per E B T0.771.090.959
Pretty Stable
Cash Ratio2.012.115.0323
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.151.0821
Slightly volatile
Debt Ratio0.06860.03470.0913
Slightly volatile

Corvus Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap140.7 M97.2 M161.5 M
Slightly volatile

Corvus Fundamental Market Drivers

Cash And Short Term Investments27.1 M

Corvus Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Corvus Pharmaceuticals Financial Statements

Corvus Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Corvus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corvus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corvus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue8 M8.4 M
Cost Of Revenue173.7 K165 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY